Azole resistance in aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles?

Clinical Infectious Diseases

Volumn 62, Issue 3, 2016, Pages 362-368

  Verweij, Paul E ^a   Chowdhary, Anuradha ^b   Melchers, Willem J G ^a   Meis, Jacques F ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF DELHI   (India)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

aspergilloma; azole fungicides; chronic pulmonary aspergillosis.; emergence of azole resistance; invasive aspergillosis

Indexed keywords

PYRROLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOMA; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE COURSE; DRUG MECHANISM; FOOD INDUSTRY; GENETIC ANALYSIS; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; ENVIRONMENTAL MICROBIOLOGY; HUMANS;

EID: 84962316213     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ885     Document Type: Article

References (60)

1. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2015; 70: 270-7
2. Patterson TF, Kirkpatrick WR, White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-60
3. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990; 12: 1147-201
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66
5. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015; 61: 1558-65
6. Walsh TJ, Anaissie EJ, Denning DW., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60
7. Schwartz S, Ruhnke M, Ribaud P., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5
8. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49: 423-33
9. Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic pulmonary aspergillosis. Mycoses 2014; 57: 257-70
10. Verweij PE, Mellado E, Melchers WJ. Multiple-Triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-3
11. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 2009; 9: 789-95
12. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 2013; 9: e1003633
13. Snelders E, Van Der Lee HA, Kuijpers J., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistancemechanism. PLoSMed 2008; 5: e219
14. Camps SM, Van Der Linden JW, Li Y., et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56: 10-6
15. Bader O, Tünnermann J, Dudakova A., et al. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother 2015; 59: 4356-9
16. Sharma C, Hagen F, Moroti R., et al. Triazole resistant Aspergillus fumigatus harbouring G54 mutation: is it De novo or environmentally acquired?. J Global Antimicrob Resist 2015; 3: 69-73
17. Howard SJ, Pasqualotto AC, Anderson MJ., et al. Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 2013; 56: 434-41
18. Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014; 9: 697-711
19. Verweij PE, Kema GH, Zwaan B, Melchers WJ. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag Sci 2013; 69: 165-70
20. Snelders E, Camps SM, Karawajczyk A., et al. Triazole fungicides can induce crossresistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7: e31801
21. Pham CD, Reiss E, Hagen F, Meis JF, Lockhart SR. Passive surveillance for azoleresistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis 2014; 20: 1498-503
22. European Centre for Disease Control (ECDC). Technical report: risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species, 2013. Available at: http: //ecdc.europa.eu/en/press/news/-layouts/forms/News-DispForm.aspx?List=8db 7286c-fe2d-476c-9133-18ff4cb1b568& ID=32. Accessed 28 August 2015
23. Lazzarini C, Esposto MC, Prigitano A, Tortorano AM. 8th Congresso Nazionale Diagnostica E Terapia dell Micosi Opportunische, Genua, Italy, 25 June 2015
24. Van Der Linden JW, Camps SM, Kampinga GA., et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20
25. Wiederhold NP, Garcia Gil V, Lindner J., et al. Evaluation of Cyp51A mechanisms of azole resistance in Aspergillus fumigatus isolates from the United States. Mycoses 2015; 58(suppl 4): 55
26. Özmerdiven GE, Ak S, Ener B., et al. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey. J Infect Chemother 2015; 21: 581-6
27. Vermeulen E, Maertens J, De Bel A., et al. Nationwide surveillance of azole resistance in Aspergillus diseases. Antimicrob Agents Chemother 2015; 59: 4569-76
28. Pelaez T, Monteiro MC, Garcia-Rubio R, Bouza E, Gomez-Lopez A, Mellado E. First detection of Aspergillus fumigatus azole-resistant strain due to cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes New Infect 2015; 6: 33-4
29. Kidd SE, Goeman E, Meis JF, Slavin MA, Verweij PE. Multi-Triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 2015; 58: 350-5
30. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol 2015; 6: 428
31. Lavergne RA, Morio F, Favennec L., et al. First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. Antimicrob Agents Chemother 2015; 59: 4331-5
32. Chowdhary A, Sharma C, Van den Boom M., et al. Multi-Azole-resistant Aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother 2014; 69: 2979-83
33. Astvad KM, Jensen RH, Hassan TM., et al. First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 2014; 58: 5096-101
34. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-8
35. Le Pape P, Lavergne RA, Morio F, Alvarez C. Description of multiple fungicidedriven alterations in azole-resistant Aspergillus fumigatus in Colombia, South America, 2015. Emerg Infect Dis 2015. In press
36. Howard SJ, Cerar D, Anderson MJ., et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76
37. Wu CJ, Wang HC, Lee JC., et al. Azole-resistant Aspergillus fumigatus isolates carrying TR34 /L98H mutations in Taiwan. Mycoses 2015; 58: 544-9
38. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine 39. Kurzyk EM, Nawrot U, Mroczynska M., et al. Detection of clinical Aspergillus fumigatus isolates resistant to triazoles. Mycoses 2015; 58(suppl 4): 53-4
39. Chowdhary A, Kathuria S, Xu J., et al. Clonal expansion and emergence of environmental multiple-Triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. PLoS One 2012; 7: e52871
40. Camps SM, Rijs AJ, Klaa", et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50: 2674-80
41. Abdolrasouli A, Rhodes J, Beale M.A., et al. Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. MBio 2015; 6: e00536
42. Mavridou E, Meletiadis J, Jancura P., et al. Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS One 2013; 8: e72280
43. Van Der Linden JW, Snelders E, Kampinga GA., et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011; 17: 1846-54
44. Steinmann J, Hamprecht A, Vehreschild MJ., et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70: 1522-6
45. Denning DW, Park S, Lass-Florl C., et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-9
46. Van Der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol 2010; 48: 1478-80
47. Chong GL, Van De Sande WW, Dingemans GJ., et al. Validation of a new Aspergillus real-Time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol 2015; 53: 868-74
48. Lepak AJ, Marchillo K, VanHecker J, Andes DR. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother 2013; 57: 5438-47
49. Van Ingen J, Van Der Lee HA, Rijs TA., et al. Azole, polyene and echinocandin MIC distributions for wild-Type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother 2015; 70: 178-81
50. Verweij PE, Ananda-Rajah M, Andes D., et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 2015; 21-22: 30-40
51. Van Der Linden JW, Arendrup MC, Warris A., et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015; 21: 1041-4
52. Russcher A, Van Paassen J, Dofferhoff PA, Kuijper EJ. High azole resistance rate of Aspergillus fumigatus at intensive care unit in a Dutch tertiary hospital. Ned Tijdschr Med Microbiol 2014; 22: S121
53. Fuhren J, Voskuil WS, Boel CH., et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015; 70: 2894-8
54. White MH, Anaissie EJ, Kusne S., et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-42
55. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15
56. Marr KA, Schlamm HT, Herbrecht R., et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-9
57. Bitar D, Lortholary O, Le Strat Y., et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20: 1149-55
58. Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) 2012; 91: 328-36
59. Van Der Linden JW, Jansen RR, Bresters D., et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 48: 1111-3
60. Gisi U. Assessment of selection and resistance risk for demethylation inhibitor fungicides in Aspergillus fumigatus in agriculture and medicine: a critical review. Pest Manag Sci 2014; 70: 352-64